Filter By:
At the iwNHL 2014, Dr Rafael Fonseca interviews Prof Keith Stewart and Prof Leif Bergsagel, all doctors with an interest in myeloma, about the application of myeloma biology and therapies in lymphoma. Prof Stewart describes tumour heterogeneity and suggests a parallel between myeloma and indolent follicular lymphoma, where the presence of a more ag...
by:EMJ | 50 views
In the recent past, lymphoma researchers have turned their attention to a phenomenon known as the “microenvironme​nt.” Made up of three factors, the microenvironmen​t involves healthy cells adjacent to the cancerous ones and helps keep the lymphoma alive in the face of treatment with chemotherapy. By releasing natural checks on the human immune syste...
by:patientpower | 114 views
The newest lymphoma drugs are very expensive and some patients may takes them for years. How can we afford these therapies. Experts share their views in this roundtable discussion. Get email alerts | http://www.p... Subscribe on YouTube | http://www.y... Like on Facebook | http://www.f.......
by:patientpower | 109 views
Today's cancer interdisciplina​ry teams are different from before. And just as there are new combinations of doctors, there are new combinations of medicines. Our roundtable of experts explains what this means for patients today. Get email alerts | http://www.p... Subsc...
by:patientpower | 88 views
Research is rushing ahead in lymphoma and this gives great hope to patients. Especially in the indolent follicular lymphoma area and also, for patients with similar CLL, new medicines are making a big difference. In this first segment of a roundtable discussion, experts explain. Get email alerts ...
by:patientpower | 68 views
Recorded at the 2014 International Workshop on Non-Hodgkin Lymphoma, Dr. Owen O’Connor gives an update on brentuximab vedotin (Adcetris), an antibody drug conjugate (ADC) approved for the treatment of CD30-positive lymphomas, like anaplastic large-cell lymphoma and Hodgkin lymphoma. Dr. O’Connor exp...
by:patientpower | 328 views
Watch as Dr. Owen O’Connor gives us an overview of the state of treatment for T-Cell lymphoma and the latest news on emerging therapies. Despite a historical challenge in treating T-cell lymphomas, Dr. O’Connor is encouraged by the recent drug approvals and ongoing clinical trials into the use of histone deacetylase (HDAC) inhibitors both as single...
by:patientpower | 356 views
Novel agents emerging for the treatment of lymphoma are offering some patients the opportunity of long-term disease control while avoiding aggressive and highly toxic chemotherapy therapies. For the time being, this means changing the goal of treatment from cure to control. Can patients live well wi...
by:patientpower | 745 views
Where are we now with treatment approaches for follicular and indolent lymphomas? What is in store for the near future? How are monoclonal antibodies changing therapy today? In this video, Dr. Wyndham Wilson, from the National Cancer Institute, joins Dr. John Gribben, from the Barts Cancer Center in London, at the 2014 International Workshop on Non...
by:patientpower | 251 views
How can you tell if you might have Follicular Lymphoma (FL), a common type of indolent non-Hodgkin lymphoma (NHL). Learn the signs and symptoms from Dr. Wyndham Wilson from the National Cancer Institute (NCI). Read the transcript | http://www.p...-...
by:patientpower | 1071 views
Please help us provide the best service.
I'm intersted in oncology videos because I'm a...

Different type of MD 
Other oncology Professional 
Something Else 

No Thanks(close window)
Membership has its privileges.
 I want the OncologyTube newsletter 

 I want to share videos & receive the newsletter 

I already have an account log me in.

username:   password: remember me

Sign In

Remember me
Forgot your password?
Not Yet a Member? Sign up for FREE here!
(Skip Ad)